Anderson-Fabry disease (AFD) is an X-linked lysosomal enzyme disorder associated with an intracellular accumulation of sphingolipids, which shorten myocardial T1 relaxation times. Myocardial affection, however, varies between different segments.
Purpose
To evaluate the specific segmental distribution and degree of segmental affection in AFD patients.
Material and Methods
Twenty-five patients with AFD, 14 patients with hypertrophic cardiomyopathy (HCM), and 21 controls were included. A Modified Look-Locker Inversion Recovery sequence (MOLLI) was used for non-enhanced T1 mapping at 1.5 T in addition to standard cardiac imaging in 10–12 short axis views. T1 values were evaluated with a mixed model ANOVA and regression analysis to determine the best diagnostic cutoff values for T1 for each myocardial segment.
Results
Regression analysis showed the best diagnostic cutoff compared to controls in cardiac segments 1–4, 8–9, and 14. Mean differences between T1 for AFD versus HCM were greatest in segment 3, 4, and 9 (99 ms, 103 ms, 86 ms, respectively). Overall T1 times were 888 ± 70 ms and 903 ± 14 ms (AFD with and without LVH); 1014 ± 17 ms and 1001 ± 22 ms (HCM and controls, P < 0.05).
Conclusion
Myocardial segments are affected by a varying degree of T1 shortening in AFD patients. Segment-specific cutoff values allow the most specific detection and quantification of the extent of myocardial affection.
SadoDMWhiteSKPiechnikSK. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging2013; 6: 392–398.
5.
WhybraCKampmannCKrummenauerF. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet2004; 65: 299–307.
6.
PicaSSadoDMMaestriniV. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson2014; 16: 99–108.
7.
SibleyCTNoureldinRAGaiN. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology2012; 265: 724–732.
8.
van OorschotJWGhoJMvan HoutGP. Endogenous contrast MRI of cardiac fibrosis: Beyond late gadolinium enhancement. J Magn Reson Imaging2014; 41: 1181–1189.
9.
Ambale-VenkateshBLimaJA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol2015; 12: 18–29.
10.
BullSWhiteSKPiechnikSK. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart2013; 99: 932–937.
11.
DassSSuttieJJPiechnikSK. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging2012; 5: 726–733.
12.
LiuSHanJNacifMS. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magn Reson2012; 14: 90–98.
13.
MilanesiMBarisonAPositanoV. Modified cine inversion recovery pulse sequence for the quantification of myocardial T1 and gadolinium partition coefficient. J Magn Reson Imaging2013; 37: 109–118.
14.
SalernoMKramerCM. Advances in parametric mapping with CMR imaging. JACC Cardiovasc Imaging2013; 6: 806–822.
15.
SechtemUMahrholdtHVogelsbergH. Cardiac magnetic resonance in myocardial disease. Heart2007; 93: 1520–1527.
16.
PiechnikSKFerreiraVMLewandowskiAJ. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson2013; 15: 13–24.
17.
ReiterUReiterGDorrK. Normal diastolic and systolic myocardial T1 values at 1.5-T MR imaging: correlations and blood normalization. Radiology2014; 271: 365–372.
18.
ThompsonRBChowKKhanA. T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging2013; 6: 637–645.
19.
MessroghliDRGreiserAFrohlichM. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging2007; 26: 1081–1086.
20.
HudsmithLEPetersenSETylerDJ. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. J Magn Reson Imaging2006; 24: 312–318.
21.
CerqueiraMDWeissmanNJDilsizianV. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation2002; 105: 539–542.
22.
AraiAELeungSKellmanP. Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction. Radiology2012; 265: 23–32.
23.
GreenJJBergerJSKramerCM. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging2012; 5: 370–377.
24.
GreulichSDeluigiCCGloeklerS. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging2013; 6: 501–511.
25.
GulatiAJabbourAIsmailTF. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA2013; 309: 896–908.
26.
SmidBEvan der TolLCecchiF. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol2014; 177: 400–408.
27.
FerreiraVMPiechnikSKDall’ArmellinaE. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging2013; 6: 1048–1058.
28.
MoonJCMessroghliDRKellmanP. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson2013; 15: 92–104.
29.
MurphyKPSzopinskiKTCohanRH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol1999; 6: 656–664.
30.
KawelNNacifMZavodniA. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson2012; 14: 27–37.
